|
The Following Paragraph was Really Important
Dr. Gabriel Hortobagyi (p. 1735, second column, 1st paragraph) My comments are in the brackets [].
"On the basis of these results [from the trials on herceptin with and after chemo], our care of patients with HER2-positive breast cancer must change today. Certainly, patients with lymph-node-positive, HER2-positive breast cancer should receive trastuzumab [herceptin] as part of optimal adjuvant systemic therapy [i.e. with taxane chemotherapy], unless the antibody is clearly contrainidcated. Patients with negative lymph nodes, whose estimated risk of recurrence after optimal chemotherapy and endocrine therapy comfortably exceeds the risk of the cardiac toxic effects of trastuzumab, should also be offered the antibody. Since most Her2-positive tumors have other adverse prognostic factors, this risk-benefit scenario is likely to apply to many patients with node-negative breast cancer."
|